FDA has granted priority review to AstraZeneca's Datroway for the first-line treatment of metastatic TNBC treatment.

Walid Kamoun, MD, PhD, and Alex Philippidis discuss AI’s Power to Lower Costs while Elucidating Tumor Progression. Invidia and Eli Lily’s Deal, Revolution Medicine’s lack of a Deal.

PharmTech spoke with Dr. Stacy Lindborg, president and CEO of IMUNON, about her experience at IMUNON, which is developing a novel DNA-based approach to treat ovarian cancer.

The companies’ “Change the Target. Change What’s Possible” targets the potential of Factor XIa inhibition in the development of treatments for thromboembolic disease.

Anthony Lakavage, executive vice president and head of Global External Affairs at USP, talks about how sustainability efforts are more than just protecting the environment and how pharmaceopeias are participating in the endeavor.

EMA recommends Kygevvi for rare thymidine kinase 2 deficiency. It is the first authorized treatment for this disease.

The EMA recommends a GLP-1 for MASH, a couple rare disease medications, and a flu vaccine among six new medicine and nine extension recommendations.

EMA recommends Rezurock (belumosudil) for chronic graft-versus-host disease, with the drug. Meetings unmet needs via conditional authorization.

The PreCheck Pilot Program is designed to strengthen the US pharmaceutical supply chain by increasing regulatory predictability and streamlining the assessment of new domestic manufacturing sites.

This week's coverage discusses the M&A report, $50B+ investments, automated cell therapy, vaccine approvals, and risks from the US leaving the WHO.

In a 2026 industry outlook interview, Raj Puri explains balancing speed with the financial and regulatory risks of accelerated drug launches via alignment.

M&A report claims that pharma is now targeting vertical integration and manufacturing control in radiopharma, GLP-1s, and ADCs to secure the supply chain.

Eli Lilly will invest $3.5 billion in a Pennsylvania facility for injectable weight-loss medicines, creating 850 new jobs and starting by 2031.

Vetter's €1.5 billion expansion adds German commercial and Illinois clinical sites to support global sterile injectable drug supply.

In a 2026 industry outlook interview, Raj Puri discusses how the tariffs hinder US pharma investment but drive demand for geographically segregated supply chains.

The ROSS CDA-200 optimizes viscous pharmaceutical batches via independent agitation, vacuum, and thermal control.

Cellares raises $257M to scale its automated manufacturing model and validate a move toward becoming an integrated development and manufacturing organization, or IDMO.

Repertoire’s T cell receptor-epitope discovery platform will be used to develop tolerizing therapy development candidates with Eli Lilly and Company.

Halo Pharma becomes a standalone drug product CDMO after the sale of Noramco’s API assets, adding sterile services by H2 2026.

With a potential US government shutdown looming, Megha Sinha, Kamet Consulting, says to treat FDA disruptions as predictable risks by protecting milestones and early readiness.

In part one of this four-part series regarding rare diseases, the author explores how rare disease treatment development evolved from a niche area to a cornerstone of biopharma growth.

With a potential US government shutdown looming, Megha Sinha, Kamet Consulting, discusses the impacts on pharma manufacturing and development.

Visit PharmTech.com for upcoming coverage of the International Day of Women and Girls in Science on February 11.

WuXi Biologics and HanchorBio partner to accelerate multi-functional fusion protein translation via end-to-end CMC and GMP services.

Laine Mello, director of Marketin, Ecolab, details how AI, continuous manufacturing, and Pharma 4.0 drive bioprocessing efficiency and cost savings.

US WHO withdrawal triggers pharma regulatory and supply chain risks while impacting global R&D collaborations.

Raj Puri, CCO, Argonaut Manufactoring, provides key insight on navigating tariffs, supply redundancy, and the risks of compressed timelines.

The European Commission has approved GSK’s adjuvanted recombinant respiratory syncytial virus vaccine, Arexvy, for use in adults aged 18 years and older.